Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Opioid Pain Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCN10A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Lentivirus) | SCN10A Lentivirus Premade Particles. For stable cell line construction. High titer, Sequence Verified. | View SCN10A Products |
| Antigen (Recombinant Protein) | SCN10A Extracellular Loop Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. HEK293 expressed (native glycosylation). | View SCN10A Products |
| Gene Delivery | SCN10A Full-Length ORF Lentivirus / Promise-ORF. Premade particles for stable Nav1.8-expressing cell lines. Preserves native conformation and membrane topology. | View SCN10A Products |
| Benchmark Ab | Anti-SCN10A Control Antibody (Recombinant). Sequence-defined clone for flow cytometry, ICC, and binding assay validation. Positive control for target binding validation. | View SCN10A Products |
| Validator | SCN10A siRNA Set. For knockdown-mediated specificity verification in electrophysiology and binding assays. | View SCN10A Products |
| Related Target: SCN9A (Nav1.7) | SCN9A Lentivirus & Protein. Synergistic pain pathway target; essential for selectivity counter-screening. | View SCN9A Products |
| Related Target: SCN5A (Nav1.5) | SCN5A Lentivirus & Protein. Cardiac sodium channel; crucial for safety and off-target toxicity assessment. | View SCN5A Products |
| Related Target: SCN11A (Nav1.9) | SCN11A Lentivirus & Protein. Compensatory sodium channel; evaluate resistance bypass and off-target liability. | View SCN11A Products |
TarMart Advantage: Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein Conformation | Lentivirus-based stable cell line generation preserves native state for Patch Clamp assays. |
| Cross-species Evaluation (Cyno / Mouse) | Human / Cyno / Mouse SCN10A ortholog lentivirus and protein available. Sequence Verified. |
| Subfamily Counter Screening (Nav1.x) | Comprehensive Nav family lentivirus panels with Sequence Verified ORFs; includes Nav1.7 (SCN9A) and Nav1.9 (SCN11A) stable cell lines. |
| Lack of Electrophysiology-Ready Controls | Premade full-length SCN10A lentivirus for automated patch-clamp and calcium-flux cell line generation. Clinical Benchmark Antibodies included. |
| False Positives / Off-Target Binding | Validated siRNA set included for target-specificity confirmation in functional assays. |
Live SCN10A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCN10A (Nav1.8) therapeutics is intensifying, with major players shifting focus from traditional opioids to small molecule sodium channel blockers. First-generation therapies like Vertex's suzetrigine (VX-548) have demonstrated efficacy in Phase III acute pain trials, validating the target. The next wave of R&D targets highly selective non-opioid analgesics with state-dependent selectivity, long-acting formulations, and rational combination strategies (e.g., Nav1.8 + Nav1.7 co-inhibition) to preempt compensatory channel upregulation. Indications are expanding from acute post-surgical pain to chronic neuropathic pain conditions (diabetic peripheral neuropathy, postherpetic neuralgia).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Nav1.8 selective) | Vertex Pharmaceuticals | Acute Pain, Neuropathic Pain | Selectivity Assay (need lentivirus for cell lines) |
| Small Molecule (Nav1.8 selective) | Latigo Biotherapeutics | Pain Management | Patch Clamp Assay (need high-titer lentivirus) |
| Small Molecule (broad Nav block) | Pfizer, Emerging Biotechs | Acute Pain, Chronic Pain, Osteoarthritis | State-Dependent Blockade Assay (need full-length Nav1.8 stable cell lines) |
| Biologic / Peptide Modulator | Preclinical Biotechs, Academic Labs | Refractory Neuropathic Pain | Conformational Cell-Surface Binding (need intact SCN10A lentivirus cell lines) |
| Gene Therapy (siRNA / ASO) | Emerging Biotechs | Chronic Pain | Knockdown Validation (need SCN10A siRNA) |
| Rational Combination (Nav1.8 + Nav1.7) | Academic-Industry Partnerships | Severe Chronic Pain, Small-Fiber Neuropathy | Dual-Target Cell Panel (need matched SCN10A + SCN9A co-expression assays) |
Target Biology & Genetic Variants
SCN10A encodes the voltage-gated sodium channel Nav1.8, which is primarily expressed in peripheral nociceptive neurons. Key functional domain: IQ domain (UniProt Q9Y5Y9), involved in calmodulin binding and channel regulation.
Key genetic variants (dbSNP):
- rs7630989: documented in UniProt VAR_020605, significance under investigation.
- rs138404783 (FEPS2): increases excitability of small DRG neurons; associated with familial episodic pain syndrome 2 (UniProt VAR_070878).
- rs35332705: documented in UniProt VAR_048696, functional impact not fully characterized.
These mutations underscore the importance of Nav1.8 in pain signaling and provide rationale for developing selective inhibitors.